These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9486105)

  • 1. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival.
    Blackstock R; Casadevall A
    Immunology; 1997 Nov; 92(3):334-9. PubMed ID: 9486105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.
    Blackstock R
    Immunology; 2003 Feb; 108(2):158-66. PubMed ID: 12562324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12.
    Blackstock R; McElwee N; Neller E; Shaddix-White J
    Infect Immun; 2000 Sep; 68(9):5146-53. PubMed ID: 10948138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R; Lees A; Pirofski L
    J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen.
    Murphy JW; Cox RA
    Clin Exp Immunol; 1988 Aug; 73(2):174-80. PubMed ID: 2460273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s).
    Khakpour FR; Murphy JW
    Infect Immun; 1987 Jul; 55(7):1657-62. PubMed ID: 2954914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
    Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
    J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans.
    Mody CH; Paine R; Jackson C; Chen GH; Toews GB
    J Immunol; 1994 Apr; 152(8):3970-9. PubMed ID: 8144964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of Cryptococcus neoformans from immunologically suppressed mice.
    Murphy JW
    Infect Immun; 1989 Jul; 57(7):1946-52. PubMed ID: 2499541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H; Zhong Z; Pirofski LA
    Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO; May RJ; Valadon P; Scharff MD
    J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
    Yauch LE; Lam JS; Levitz SM
    PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells.
    Murphy JW; Mosley RL; Moorhead JW
    J Immunol; 1983 Jun; 130(6):2876-81. PubMed ID: 6222119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells.
    Vecchiarelli A; Pietrella D; Bistoni F; Kozel TR; Casadevall A
    Immunology; 2002 Jun; 106(2):267-72. PubMed ID: 12047756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen.
    Murphy JW; Moorhead JW
    J Immunol; 1982 Jan; 128(1):276-83. PubMed ID: 6172483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans.
    Murphy JW; Schafer F; Casadevall A; Adesina A
    Infect Immun; 1998 Jun; 66(6):2632-9. PubMed ID: 9596727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
    Deshaw M; Pirofski LA
    Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
    Pirofski LA
    Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.